Tirzepatide 30MG

Product Overview

Tirzepatide 30MG is a synthetic dual GIP/GLP-1 receptor-agonist research material, supplied as white to off-white lyophilised powder in a 30mg catalogue presentation (SKU TR30). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

Tirzepatide research examines coordinated GIP- and GLP-1-receptor signalling, glucose-dependent cellular responses and metabolic regulation. The published literature includes controlled human trials, but these do not validate an independently supplied lyophilised research vial.

Identity and Specifications

• Product: Tirzepatide 30MG
• SKU: TR30
• Format: White to off-white lyophilised powder
• Synonyms: Tirzepatide, LY3298176, dual GIP/GLP-1 receptor agonist
• Catalogue purity specification: ≥99%
• CAS number: 2023788-19-2
• Molecular formula: C225H348N48O68
• Molecular weight: 4813 g/mol
• Amount: 30mg

Catalogue Distinction

This is the 30mg listing for this identity. Related catalogue amounts are Tirzepatide 10mg and Tirzepatide 20mg; each has its own SKU. The amount difference is not a dose recommendation. Unless a batch certificate states otherwise, the scientific identity and research limitations are shared while the quantity supplied differs.

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• GIP- and GLP-1-receptor pharmacology
• glucose-dependent signalling and endocrine-cell responses
• metabolic and energy-regulation pathways
• comparative receptor-agonist study design

Evidence Quality and Limitations

The evidence base includes extensive clinical development of authorised pharmaceutical formulations. Those data establish neither equivalence nor suitability of this ExtolX research material.

Regulatory Context

UK-authorised tirzepatide medicines are finished, regulated formulations with defined excipients, delivery systems and approved labelling. This lyophilised research material is not equivalent to those medicines and is not supplied for administration.

Storage and Handling

Before reconstitution: Keep the lyophilised vial sealed, dry and protected from light at −20°C, subject to the batch-specific supplier documentation. Published tirzepatide reference data use the sodium salt, but the exact salt and formulation of this ExtolX batch have not been confirmed.

After reconstitution: The published sodium-salt reference advises against storing aqueous solution for more than one day. Because formulation agreement has not been established, prepare solution fresh where the validated method permits and do not assume a longer hold time. Record the solvent, concentration, preparation time, temperature and container used.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• Cayman Chemical: tirzepatide sodium-salt storage and solution guidance
• SURPASS-1 randomised trial (PMID 34186022)
• Phase 2 receptor-agonist trial (PMID 30293770)
• Tirzepatide 10MG
• Tirzepatide 20MG
• UK SmPC: tirzepatide (Mounjaro)

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.